Jazz Pharmaceuticals Sleep Medicine Presentatio
Drug Updates

Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023. One of the accepted abstracts provided a comprehensive review of clinical data that assessed the impact of oxybate on sleep quality, sleep architecture and measures […]

Drug Updates

AstraZeneca appoints Ram Mudaliar as the India Lead of its Clinical Data & Insights (CDI) Division

AstraZeneca India Private Limited, the services arm of AstraZeneca, a leading science-led biopharmaceutical company, today announced the appointment of Ram Mudaliar as the India lead of their Clinical Data & Insights (CDI) division. Prior to his appointment as the CDI India Lead, Ram worked with AstraZeneca Canada, managing delivery of the Lung portfolio and leading […]